CTKB
Cytek Biosciences, Inc. Common Stock
Nasdaq · usd
Cytek Biosciences, Inc. Common Stock (CTKB) trades at $6.12 (-3.16%) as of 7:53:00 PM EST on Nov 20, 2026, +12.71% over the past month. Market cap is $800.4M, with 3.6 days to cover in short interest.
Stock performance
How Cytek Biosciences, Inc. Common Stock (CTKB) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.16%
- 1W
- +4.79%
- 1M
- +12.71%
- YTD
- +21.19%
- 1Y
- +4.79%
- 52-wk range
- $3.31 – $6.39
Key statistics
Today's trading snapshot for CTKB: day range, open, previous close, volume and market cap.
- Day range
- $5.99 – $6.39
- Open
- $6.31
- Prev close
- $6.32
- Volume
- 1.77M
- Market cap
- $800.4M
- Shares out
- 130.78M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Cytek Biosciences, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 3.85
- P/B
- 2.49
- P/FCF
- —
- ROE
- -25.3%
- ROA
- -18.2%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 20, 2026
8-K filings
Material corporate events Cytek Biosciences, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 4, 2026
On November 4, 2026, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Bylaw amendmentSep 29, 2026
On September 23, 2026, the board of directors of Cytek Biosciences, Inc. unanimously adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date. The amendments included additional information and representations for stockholder proposals and director nominees, expanded the chairperson’s authority to disregard non-compliant nominations and proposals, incorporation of the universal proxy rules, and advance-notice and disqualification procedures for special-meeting nominations.
- Material litigationAug 24, 2026
On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36.11 million in royalties.
- Executive officer departureJul 15, 2026
Valerie Barnett's position as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, Inc. (the "Company") terminated on June 29, 2026.
- Executive officer departureJun 25, 2026
On June 18, 2026, Valerie Barnett and Cytek Biosciences, Inc. (the "Company") agreed that Ms. Barnett's position as Chief Legal Officer and Corporate Secretary of the Company would terminate effective as of June 29, 2026. Ms. Barnett's separation is not due to any disagreement with the Company's operations, policies or practices.
CTKB short interest
How heavily CTKB is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.6
- Short interest
- 4.11M
- Avg volume
- 1.15M
As of · reported to FINRA twice monthly.
CTKB news
The latest news and headlines about Cytek Biosciences, Inc. Common Stock (CTKB).
- Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the YearpositiveGlobeNewswire Inc.· Nov 5, 2026
- Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out fornegativeZacks Investment Research· Oct 28, 2026
- Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026positiveGlobeNewswire Inc.· Jun 2, 2026
- Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional ImpactpositiveGlobeNewswire Inc.· Mar 9, 2026
- Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue ResultspositiveGlobeNewswire Inc.· Jan 12, 2026
Frequently asked questions
What is the Cytek Biosciences, Inc. Common Stock (CTKB) stock price today?
Cytek Biosciences, Inc. Common Stock (CTKB) is trading at $6.12 (-3.16% on the day) as of 7:53:00 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Cytek Biosciences, Inc. Common Stock?
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single…
What is the short interest in CTKB?
As of Oct 30, 2026, CTKB has 4.11M shares short and 3.6 days to cover.
What exchange is CTKB listed on?
Cytek Biosciences, Inc. Common Stock (CTKB) trades on Nasdaq in USD, in the LABORATORY ANALYTICAL INSTRUMENTS industry.
Build with AI
Build an analysis of CTKB with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CTKB analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.